|
Barbara Morin is the Director of Quality Assurance and Regulatory Affairs at NPI. Barbara has an undergraduate degree in biology from Clark University and a Master's degree in pharmacology from Northeastern University where she graduated summa cum laude as a member of Rho Chi.
Barbara started her career in the pharmaceutical field at the OTC firm of Otis Clapp and Sons where she eventually ran the QC laboratory. Barbara then joined Muro Pharmaceutical to start up their stability group. Muro Pharmaceutical specializes in pharmaceuticals for the upper respiratory tract and asthma. After that she held several positions at Muro including both Director of QA and Director of QC. When she left Muro she had a staff of 22 people, which included quality assurance, quality control and compliance groups. During her tenure at Muro she developed the formulation for Prelone 5 and was instrumental in getting Muro's product Prelone to be adopted into the USP. Barbara also represented the quality group for FDA inspections.
After her stay at Muro she worked for a brief time at Formatech Inc. where she was the Director of QA and RA. Formatech Inc. is a contract manufacturer of aseptic and lypholyzed products for clinical supplies.
Barbara joined NPI in August 2002 as the Director of QA. In December she became the Director of QA and Regulatory Affairs taking over the responsibilities of both departments. Barbara has been instrumental in bringing the contract manufacture of the API semi-synthetic Paclitaxel on line and is now working on quality development of quality systems to bring primary taxanes production on line at Natural Pharma Canada's Vancouver facility. | 